Volpara Solutions Hits International Milestone with Installation in 31st Country

Share Article

Records Installations of VolparaDensity at Sites in Canada, Belgium, Turkey, United Kingdom, Korea, and Japan

News Image
"We've been using Volpara at our imaging clinic for the past nine months and we have full confidence in Volpara's automated, volumetric density assessments of our patients’ mammograms," said Dr Cuigniez.

Demonstrating the growing adoption of volumetric breast density and quantitative breast imaging tools, Volpara Solutions today announced the installation of VolparaDensity in Belgium. With new installations also recently completed in Canada, Turkey, Korea, Japan and the United Kingdom, Volpara Solutions’ technology is now in use in 31 countries and more than 4-million women have had their breast density analyzed using VolparaDensity.

"We've been using Volpara at our imaging clinic for the past nine months and we have full confidence in Volpara's automated, volumetric density assessments of our patients’ mammograms. My staff has been very pleased with Volpara's ease of installation and simplicity of operation,” notes Dr Francis Cuigniez of Ghent, Belgium. “Additionally, Volpara has been integrated with our RIS to automatically include breast density scores into the results report that is shared with patients and their referring physicians.”

According to Dr Cuigniez, who participates in the official screening program organized by the Flemish Health System offering free mammograms on a biennial basis, “we counsel patients whose breast density scores fall within the ACR Breast Density Categories of "C" and "D" about their increased risk of breast cancer and recommend they talk with their doctors about the possible need for additional imaging, such as ultrasound. In the future, I believe it's conceivable that adjunctive ultrasound reimbursement will only be approved for patients who have very dense breasts. Having Volpara installed helps us to establish future billing profiles and justifications for additional imaging procedures," Dr Cuigniez added.

Cleared by the FDA, HealthCanada, the TGA and CE-marked, VolparaDensity is in use at breast imaging centers worldwide to help radiologists objectively assess density from both digital mammography and tomosynthesis images to help doctors evaluate who might benefit from additional screening. Highly correlated to breast MR assessments, VolparaDensity is a reliable tool that automatically generates an objective measurement of volumetric breast density correlated to the American College of Radiology (ACR) breast composition categories.

“We are very pleased that Dr. Cuigniez’s practice marks the 31st country where VolparaDensity and our suite of quantitative breast imaging solutions have been adopted, demonstrating the passion and commitment of breast health professionals globally to use state-of-the-art technology to provide the best breast health care for their patients,” said Don Alvarez, vice president, APAC and EMEA, Volpara Solutions.

About Volpara Solutions
Founded to enable radiologists to give women the most accurate information possible regarding their breast health, Volpara Solutions is the wholly owned sales and marketing arm of Matakina Technology Limited of New Zealand. Cleared by the FDA, HealthCanada, the TGA, and CE-marked, VolparaDensity provides an objectively volumetric measure of breast density from both digital mammography and tomosynthesis images. VolparaDensity is part of a suite of quantitative breast imaging tools built on the Volpara Solutions algorithm that allows for personalized measurements of density, patient dose, breast compression and other factors designed to help maintain accuracy and consistent quality in breast screening. For more information, visit http://www.volparasolutions.com

# # #

Volpara Solutions                     
Chris K. Joseph                        

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Chris K Joseph
Like >
Visit website